The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...

New research reveals insomnia's deep links to cardiovascular health, urging us to treat it as a core medical issue, not a ...

"We've greatly misjudged and mis-prioritized the mental health of mothers in general and we've gotten a lot of it wrong." ...

Researchers identified SGK1 as a key chemical connecting childhood trauma to depression and suicidal behavior. High SGK1 ...

What’s confusing is that people who stop taking antidepressants can experience flu-like withdrawal symptoms as the body ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

To provide some solid data, the authors of the new study gave LSD to a group of patients in New Zealand, and instructed them ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Three medical experts review the evidence around how antidepressants may affect the gut microbiome, and what this could mean ...

A neuroscientist, he employed a battery of high-tech tools in devising a fast-acting therapy that targets the area of the ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind” or the "Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics ...

Millions of Americans with anxiety and depression struggle to find the right medication. The best fit may depend on your ...